2024 |
- Kiviaho, A, Eerola, SK, Kallio, HML, Andersen, MK, Hoikka, M, Tiihonen, AM et al.. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15 (1):9949. doi: 10.1038/s41467-024-54364-1. PubMed PMID:39550375 PubMed Central PMC11569175.
- Murtola, TJ, Siltari, A, Raittinen, P, Tammela, TLJ, Linder, S, Csizmarik, A et al.. Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer. Eur Urol Open Sci. 2024;70 :135-141. doi: 10.1016/j.euros.2024.10.010. PubMed PMID:39525979 PubMed Central PMC11547961.
- Lawlor, A, Beyer, K, Russell, B, Steinbeisser, C, Bjartell, A, De Meulder, B et al.. PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research. Nat Rev Urol. 2024; :. doi: 10.1038/s41585-024-00925-4. PubMed PMID:39251785 .
- Ahtinen, M, Vironen, J, Murtola, TJ. Previous inguinal hernia surgery does not limit the likelihood of choosing prostatectomy as primary prostate cancer therapy. Sci Rep. 2024;14 (1):9943. doi: 10.1038/s41598-024-60451-6. PubMed PMID:38688937 PubMed Central PMC11061137.
- Jussila, I, Ahtiainen, JP, Laakkonen, EK, Siltari, A, Kaipia, A, Jokela, T et al.. Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol. BJU Int. 2024;134 (1):110-118. doi: 10.1111/bju.16361. PubMed PMID:38587276 .
- Auvinen, A, Tammela, TLJ, Mirtti, T, Lilja, H, Tolonen, T, Kenttämies, A et al.. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. JAMA. 2024;331 (17):1452-1459. doi: 10.1001/jama.2024.3841. PubMed PMID:38581254 PubMed Central PMC10999002.
- Wang, Y, Chen, J, Gong, L, Wang, Y, Siltari, A, Lou, YR et al.. MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC. J Nanobiotechnology. 2024;22 (1):145. doi: 10.1186/s12951-024-02438-z. PubMed PMID:38566211 PubMed Central PMC10985917.
- Pajunen, H, Veitonmäki, T, Huhtala, H, Nikkola, J, Pöyhönen, A, Murtola, T et al.. Prognostic factors of renal cell cancer in elderly patients: a population-based cohort study. Sci Rep. 2024;14 (1):6295. doi: 10.1038/s41598-024-56835-3. PubMed PMID:38491173 PubMed Central PMC10942969.
- Löffeler, S, Bertilsson, H, Müller, C, Aas, K, Haugnes, HS, Aksnessæther, B et al.. Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P). BJU Int. 2024;133 (6):680-689. doi: 10.1111/bju.16314. PubMed PMID:38469686 .
- Russell, B, Beyer, K, Lawlor, A, Roobol, MJ, Venderbos, LDF, Remmers, S et al.. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?. Eur Urol Open Sci. 2024;59 :27-29. doi: 10.1016/j.euros.2023.11.004. PubMed PMID:38298764 PubMed Central PMC10829596.
- Nolsøe, AB, Holm, HV, Murtola, TJ, Østergren, PB, Fode, M. Management of functional outcomes after radical prostatectomy in the Nordic countries: A survey of uro-oncological centers. Int J Impot Res. 2024;36 (5):486-492. doi: 10.1038/s41443-023-00772-8. PubMed PMID:37816870 PubMed Central PMC11251983.
- Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and prostate cancer survival in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2024;27 (1):73-80. doi: 10.1038/s41391-022-00597-4. PubMed PMID:36131010 PubMed Central PMC10876474.
2023 |
- Murto, MO, Simolin, N, Arponen, O, Siltari, A, Artama, M, Visvanathan, K et al.. Statin Use, Cholesterol Level, and Mortality Among Females With Breast Cancer. JAMA Netw Open. 2023;6 (11):e2343861. doi: 10.1001/jamanetworkopen.2023.43861. PubMed PMID:37976058 PubMed Central PMC10656638.
- Siltari, A, Murtola, TJ, Kausz, J, Talala, K, Taari, K, Tammela, TL et al.. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men. Acta Oncol. 2023;62 (12):1898-1904. doi: 10.1080/0284186X.2023.2278189. PubMed PMID:37971326 .
- Peltomaa, AI, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Statin use and outcomes of oncological treatment for castration-resistant prostate cancer. Sci Rep. 2023;13 (1):18866. doi: 10.1038/s41598-023-45958-8. PubMed PMID:37914793 PubMed Central PMC10620176.
- Nolsøe, AB, Holm, HV, Murtola, TJ, Østergren, PB, Fode, M. Management of functional outcomes after radical prostatectomy in the Nordic countries: A survey of uro-oncological centers. Int J Impot Res. 2024;36 (5):486-492. doi: 10.1038/s41443-023-00772-8. PubMed PMID:37816870 PubMed Central PMC11251983.
- Haapiainen, H, Murtola, TJ, Koskimäki, J, Riikonen, J, Pakarainen, T, Haney, CM et al.. Robot-assisted versus three-dimensional laparoscopic radical prostatectomy: 12-month outcomes of a randomised controlled trial. BJU Int. 2023;132 (5):505-511. doi: 10.1111/bju.16132. PubMed PMID:37461186 .
- Nikulainen, I, Salminen, AP, Seikkula, H, Högerman, M, Perez, IM, Koskinen, I et al.. Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland. Acta Oncol. 2023;62 (8):829-835. doi: 10.1080/0284186X.2023.2228446. PubMed PMID:37377029 .
- Valli, J, Haapiainen, H, Murtola, TJ, Huhtala, H, Kaipia, A, Raitanen, M et al.. Visual Analogue Scale and Expanded Prostate Cancer Index Composite-26 in the Evaluation of Urinary Continence Recovery After Three-Dimensional Laparoscopic Radical Prostatectomy, a Single-Center Prospective Registered Study. Urology. 2023;177 :103-108. doi: 10.1016/j.urology.2023.04.021. PubMed PMID:37146729 .
- Sattari, M, Kohvakka, A, Moradi, E, Rauhala, H, Urhonen, H, Isaacs, WB et al.. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases. Endocr Relat Cancer. 2023;30 (8):. doi: 10.1530/ERC-22-0247. PubMed PMID:37140987 PubMed Central PMC10326635.
- Nätkin, R, Pennanen, P, Syvälä, H, Bläuer, M, Kesseli, J, Tammela, TLJ et al.. Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation. PLoS One. 2023;18 (2):e0281645. doi: 10.1371/journal.pone.0281645. PubMed PMID:36809527 PubMed Central PMC9942993.
- Joentausta, RM, Siltari, A, Rannikko, A, Murtola, TJ. Incidence of erectile dysfunction treatment after radical prostatectomy by Statin use in Finnish Nationwide Cohort Study. Scand J Urol. 2023;57 (1-6):53-59. doi: 10.1080/21681805.2023.2168746. PubMed PMID:36683437 .
- Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 2023;83 (3):246-258. doi: 10.1002/pros.24456. PubMed PMID:36325820 .
- Siltari, A, Lönnerbro, R, Pang, K, Shiranov, K, Asiimwe, A, Evans-Axelsson, S et al.. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2023;21 (2):316.e1-316.e11. doi: 10.1016/j.clgc.2022.09.006. PubMed PMID:36243664 .
2022 |
- Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 2023;83 (3):246-258. doi: 10.1002/pros.24456. PubMed PMID:36325820 .
- Siltari, A, Lönnerbro, R, Pang, K, Shiranov, K, Asiimwe, A, Evans-Axelsson, S et al.. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2023;21 (2):316.e1-316.e11. doi: 10.1016/j.clgc.2022.09.006. PubMed PMID:36243664 .
- Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and prostate cancer survival in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2022; :. doi: 10.1038/s41391-022-00597-4. PubMed PMID:36131010 .
- Siltari, A, Syvälä, H, Lou, YR, Gao, Y, Murtola, TJ. Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor’s Immune Environment. Cancers (Basel). 2022;14 (17):. doi: 10.3390/cancers14174293. PubMed PMID:36077824 PubMed Central PMC9454444.
- Latvala, L, Tiihonen, M, Murtola, TJ, Hartikainen, S, Tolppanen, AM. Use of α1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer’s disease. Pharmacoepidemiol Drug Saf. 2022;31 (10):1110-1120. doi: 10.1002/pds.5503. PubMed PMID:35751619 PubMed Central PMC9542191.
- Peltomaa, AI, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. Cancers (Basel). 2022;14 (12):. doi: 10.3390/cancers14122920. PubMed PMID:35740586 PubMed Central PMC9221017.
- Salminen, JK, Mehtola, A, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. Br J Cancer. 2022;127 (4):704-711. doi: 10.1038/s41416-022-01817-3. PubMed PMID:35505251 PubMed Central PMC9381528.
- Siltari, A, Riikonen, J, Koskimäki, J, Pakarainen, T, Ettala, O, Boström, P et al.. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open. 2022;12 (4):e050264. doi: 10.1136/bmjopen-2021-050264. PubMed PMID:35487730 PubMed Central PMC9058683.
- Ahtinen, M, Vironen, J, Murtola, TJ. The risk of inguinal hernia repair after radical prostatectomy – a population-based cohort study. Scand J Urol. 2022;56 (3):191-196. doi: 10.1080/21681805.2022.2065357. PubMed PMID:35451920 .
- Eskelinen, T, Veitonmäki, T, Kotsar, A, Tammela, TLJ, Pöyhönen, A, Murtola, TJ et al.. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 2022;33 (2):313-320. doi: 10.1007/s10552-021-01527-w. PubMed PMID:34921656 PubMed Central PMC8776666.
- Salminen, JK, Murtola, TJ. Reply to: Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2022;150 (7):1214. doi: 10.1002/ijc.33887. PubMed PMID:34854487 .
- Vettenranta, A, Murtola, TJ, Raitanen, J, Raittinen, P, Talala, K, Taari, K et al.. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncol. 2022;8 (1):61-68. doi: 10.1001/jamaoncol.2021.5672. PubMed PMID:34817559 PubMed Central PMC8777566.
2021 |
- Joentausta, RM, Rannikko, A, Murtola, TJ. Prostate Cancer-specific Survival After Radical Prostatectomy Is Improved Among Metformin Users but Not Among Other Antidiabetic Drug Users. Eur Urol Open Sci. 2021;34 :86-93. doi: 10.1016/j.euros.2021.10.002. PubMed PMID:34934970 PubMed Central PMC8655383.
- Eskelinen, T, Veitonmäki, T, Kotsar, A, Tammela, TLJ, Pöyhönen, A, Murtola, TJ et al.. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 2022;33 (2):313-320. doi: 10.1007/s10552-021-01527-w. PubMed PMID:34921656 PubMed Central PMC8776666.
- Salminen, JK, Murtola, TJ. Reply to: Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2022;150 (7):1214. doi: 10.1002/ijc.33887. PubMed PMID:34854487 .
- Jasu, J, Tolonen, T, Antonarakis, ES, Beltran, H, Halabi, S, Eisenberger, MA et al.. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021;30 :47-62. doi: 10.1016/j.euros.2021.05.011. PubMed PMID:34337548 PubMed Central PMC8317817.
- Enwald, M, Lehtimäki, T, Mishra, PP, Mononen, N, Murtola, TJ, Raitoharju, E et al.. Human Prostate Tissue MicroRNAs and Their Predicted Target Pathways Linked to Prostate Cancer Risk Factors. Cancers (Basel). 2021;13 (14):. doi: 10.3390/cancers13143537. PubMed PMID:34298752 PubMed Central PMC8307951.
- Murtola, TJ, Siltari, A. Statins for Prostate Cancer: When and How Much?. Clin Cancer Res. 2021;27 (18):4947-4949. doi: 10.1158/1078-0432.CCR-21-1891. PubMed PMID:34281913 .
- Raittinen, PVH, Syvälä, H, Tammela, TLJ, Häkkinen, MR, Ilmonen, P, Auriola, S et al.. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine. 2021;68 :103432. doi: 10.1016/j.ebiom.2021.103432. PubMed PMID:34144486 PubMed Central PMC8219992.
- Santala, EEE, Artama, M, Pukkala, E, Visvanathan, K, Staff, S, Murtola, TJ et al.. Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients-A Nationwide Cohort Study. Cancers (Basel). 2021;13 (9):. doi: 10.3390/cancers13092087. PubMed PMID:33925829 PubMed Central PMC8123393.
- Vettenranta, A, Murtola, TJ, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of prostate cancer screening among men using antidiabetic medication. Sci Rep. 2021;11 (1):7363. doi: 10.1038/s41598-021-86534-2. PubMed PMID:33795720 PubMed Central PMC8016840.
- Haapiainen, H, Murtola, TJ, Raitanen, M. 3D laparoscopic prostatectomy: A prospective single-surgeon learning curve in the first 200 cases with oncologic and functional results. Scand J Urol. 2021;55 (3):242-248. doi: 10.1080/21681805.2021.1898465. PubMed PMID:33792488 .
- Peltomaa, AI, Raittinen, P, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study. Prostate Cancer Prostatic Dis. 2021;24 (3):917-924. doi: 10.1038/s41391-021-00351-2. PubMed PMID:33790420 PubMed Central PMC8384625.
- Vihervuori, VJ, Talala, K, Taari, K, Lahtela, J, Tammela, TLJ, Auvinen, A et al.. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiol Biomarkers Prev. 2021;30 (5):982-989. doi: 10.1158/1055-9965.EPI-19-0580. PubMed PMID:33653815 .
- Salminen, JK, Kuoppamäki, V, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2021;149 (2):307-315. doi: 10.1002/ijc.33535. PubMed PMID:33634851 .
- Siltari, A, Auvinen, A, Murtola, TJ. Pharmacoepidemiological Evaluation in Prostate Cancer-Common Pitfalls and How to Avoid Them. Cancers (Basel). 2021;13 (4):. doi: 10.3390/cancers13040696. PubMed PMID:33572236 PubMed Central PMC7914977.
- Siltari, A, Riikonen, J, Murtola, TJ. Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Sexual Function – A Randomized Clinical Trial. J Sex Med. 2021;18 (2):327-338. doi: 10.1016/j.jsxm.2020.11.003. PubMed PMID:33358241 .
2020 |
- Siltari, A, Riikonen, J, Murtola, TJ. Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Sexual Function – A Randomized Clinical Trial. J Sex Med. 2021;18 (2):327-338. doi: 10.1016/j.jsxm.2020.11.003. PubMed PMID:33358241 .
- Santala, EEE, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland. Cancer Epidemiol Biomarkers Prev. 2020;29 (11):2376-2382. doi: 10.1158/1055-9965.EPI-20-0711. PubMed PMID:32917663 .
- Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS One. 2020;15 (6):e0234269. doi: 10.1371/journal.pone.0234269. PubMed PMID:32598349 PubMed Central PMC7323967.
- Riikonen, J, Pakarainen, T, Siltari, A, Pienimäki, JP, Koskimäki, J, Murtola, TJ et al.. Urine colour as an indicator for anastomotic leakage after robot-assisted radical prostatectomy. Scand J Urol. 2020;54 (3):201-207. doi: 10.1080/21681805.2020.1750474. PubMed PMID:32308088 .
- Kinnunen, PT, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Anticoagulants and Breast Cancer Survival: A Nationwide Cohort Study. Cancer Epidemiol Biomarkers Prev. 2020;29 (1):208-215. doi: 10.1158/1055-9965.EPI-19-0147. PubMed PMID:31653681 .
- Santala, EEE, Rannikko, A, Murtola, TJ. Reply to: Calcium channel blockers therapy and the risk of prostate cancer death. Int J Cancer. 2020;146 (4):1175. doi: 10.1002/ijc.32745. PubMed PMID:31633796 .